Vectren 2010 Annual Report Download - page 114

Download and view the complete annual report

Please find page 114 of the 2010 Vectren annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 128

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128

112
Shares Issuable under Share-Based Compensation Plans
As of December 31, 2010, the following shares were authorized to be issued under share-based compensation plans:
Plan category
Equity compensation plans approved by
security holders 929,806
(1)
24.55$
(1)
2,302,674
(2)
Equity compensation plans not approved
by security holders - - -
Total 929,806 24.55$ 2,302,674
AB C
Number of securities to
be issued upon exercise
of outstanding options,
warrants and rights
Weighted average
exercise price of
outstanding options,
warrants and rights
Number of securities remaining
available for future issuance
under equity compensation
plans (excluding securities
reflected in column (a))
(1) Under the Vectren At-Risk Compensation Plan, the Company may buy shares on the open market during periods when there are no
restrictions on insider transactions to fulfill these obligations.
(2) On February 14, 2011, 219,700 restricted units were approved to be issued to management by the Compensation and Benefits
Committee of the Board of Directors. In addition, on February 14, 2011, participants forfeited 95,182 shares related to awards
measured during the three year performance period ending December 31, 2010. The issuance and forfeiture of the shares on February
14, 2011 are not included in the above table.
The At-Risk Compensation plan was approved by Vectren Corporation common shareholders after the merger forming Vectren
and was reapproved at the 2006 annual meeting of shareholders.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE
Information required by Part III, Item 13 of this Form 10-K is incorporated by reference herein, and made part of this Form 10-K,
from the Company's Proxy Statement for its 2011 Annual Meeting of Stockholders, which will be filed with the Securities and
Exchange Commission pursuant to Regulation 14A, within 120 days after the end of the fiscal year.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Information required by Part III, Item 14 of this Form 10-K is incorporated by reference herein, and made part of this Form 10-K,
from the Company's Proxy Statement for its 2011 Annual Meeting of Stockholders, which will be filed with the Securities and
Exchange Commission pursuant to Regulation 14A, within 120 days after the end of the fiscal year.
PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
List of Documents Filed as Part of This Report
Consolidated Financial Statements
The consolidated financial statements and related notes, together with the report of Deloitte & Touche LLP, appear in Part II
“Item 8 Financial Statements and Supplementary Data” of this Form 10-K.
Supplemental Schedules
For the years ended December 31, 2010, 2009, and 2008, the Company’s Schedule II -- Valuation and Qualifying Accounts
Consolidated Financial Statement Schedules is presented herein. The report of Deloitte & Touche LLP on the schedule may be
found in Item 8. All other schedules are omitted as the required information is inapplicable or the information is presented in the
Consolidated Financial Statements or related notes in Item 8.